MEMORANDUM:

Subject: Efficacy Review for 6459-G/Rentokil Calmic Type S Formulation - Cascade
DP Barcode: D249413

From: Srinivas Gowda, Microbiologist
Efficacy and Science Support Branch
Efficacy Evaluation Team
Antimicrobials Division (7510C)

To: Robert Brennis, PM 32/Kathryn Scanlon
Regulatory Management Branch II
Antimicrobials Division (7510C)

Thru: John W. Newland III, Team Leader
Efficacy and Science Support Branch
Efficacy Evaluation Team
Antimicrobials Division (7510C)

Michele E. Wingfield, Branch Chief
Efficacy and Science Support Branch
Antimicrobials Division (7510C)

Applicant: Rentokil Ltd.
West Sussex, England

FORMULATION FROM LABEL:

<table>
<thead>
<tr>
<th>Active Ingredient(s):</th>
<th>% by wt.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Irgasan DP 300 R</td>
<td>01.00</td>
</tr>
</tbody>
</table>

Inert Ingredient(s):

| Total: 99.00 |

Total: 100.00
BACKGROUND: Product manager has requested review of efficacy data (MRID Nos. 446321-11 and 446321-12) to support the proposed label claims.

RECOMMENDATIONS: EASSB findings are:

The claims on the proposed label are not related to human health and therefore, the submitted data were not reviewed or accepted. However, registrants are required to keep these data on their file. The Agency retains the right to call such data any time.

Labeling:

Revise the statement "For use only in Calmic Sanitizer Unit" to read "For use only in Calmic Sanitizer Unit for bacteriostatic odor control associated with human wastes".

Expand the abbreviation, "WCs".

Under the heading "Directions for Use" include the concentration of the product required to provide effectiveness and the frequency of treatment required.